Inhibitory Antibodies
Products for Inhibitory Antibodies
- Cat.No. Product Name Information
- GC66199 Alemtuzumab Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52, a glycoprotein expressed on the surface of most lymphoid, and to a lesser extent, myeloid cell types. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes.
- GC68370 Amatuximab
- GC68343 Anifrolumab
- GC66388 Anti-Mouse CTLA-4 Antibody Anti-Mouse CTLA-4 Antibody is an anti-mouse CTLA-4 IgG2b antibody inhibitor derived from host mouse.
- GC66336 Anti-Mouse NK1.1 Antibody Anti-Mouse NK1.1 Antibody is an anti-mouse NK1.1 IgG2a antibody inhibitor derived from host mouse.
- GC68347 ATG-031
- GC66359 Atibuclimab Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis. Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist.
-
GC65061
Blinatumomab
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody which can specifically targets the CD19 antigen present on B cells. Blinatumomab can be used for the research of acute lymphoblastic leukemia.
- GC66384 Blosozumab Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis.
- GC67763 Burosumab
- GC68345 Caplacizumab
- GC66380 Emactuzumab Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) .
- GC68334 Enoblituzumab
- GC64479 Gemtuzumab ozogamicin Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic derivative of Calicheamicin. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia.
- GC63009 Human IgG1 kappa, Isotype Control Human IgG1 kappa, Isotype Control, a human monoclonal antibody, is an isotype control for human IgG1κ antibody.
- GC65240 Human IgG4 kappa, Isotype Control Human IgG4 kappa, Isotype Control, a human monoclonal antibody, is an isotype control for human IgG4κ antibody.
- GC68367 Ieramilimab
-
GC69355
Landogrozumab
Landogrozumab (LY2495655) is a humanized monoclonal antibody against myostatin, which effectively improves muscle volume, grip strength and function. Landogrozumab can be used in research related to muscle atrophy diseases.
- GC66358 Lemzoparlimab Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity.
- GC68368 Magrolimab
- GC66351 Mosunetuzumab Mosunetuzumab (BTCT-4465A) is a humanized, immunoglobulin G1-based bispecific antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs).
- GC68338 Naxitamab
- GC68357 Nesvacumab
- GC68301 Nipocalimab
-
GC69604
Ociperlimab
Ociperlimab is a humanized IgG1 antibody against TIGIT. Ociperlimab binds with high affinity to the extracellular domain of human TIGIT (KD = 0.135 nM). It blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used for cancer research.
- GC65498 Ofatumumab Ofatumumab (Arzerra) is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes.
- GC66330 Omburtamab Omburtamab is an anti-CD276 (also known as B7-H3) monoclonal antibody, CD276 is a B7/CD28 immunoglobulin superfamily member expressed among solid human tumours. Omburtamab can bind tumor tissues and be used in various cancers research.
-
GC69626
Ontuxizumab
Ontuxizumab (MORAb-004) is a monoclonal antibody of the IgG1/κ class that targets tumor endothelial markers 1 (TEM-1) or CD248 and has anti-tumor effects. Ontuxizumab can be used in cancer research.
-
GC69628
Opicinumab
Opicinumab (BIIB033) is a monoclonal antibody that targets LINGO-1 and has potential applications in acute optic neuritis and relapsing multiple sclerosis.
-
GC69632
Orilanolimab
Orilanolimab (SYNT001) is a humanized, de-immunized monoclonal antibody that blocks FcRn. Orilanolimab inhibits the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impairs FcRn-mediated adaptive immune function activated by IgG ICs. Orilanolimab can disrupt IgG homeostasis and innate and adaptive immunity.
-
GC69664
Pascolizumab
Pascolizumab (SB-240683) is a humanized monoclonal antibody against IL-4. Pascolizumab has potential for asthma research.
-
GC69685
Pepinemab
Pepinemab (VX 15/2503) is a humanized monoclonal antibody against SEMA4D, also known as CD100. SEMA4D is a signaling protein that regulates neuronal development and plays a role in various cellular processes. Pepinemab can be used for research on neurodegenerative diseases such as Alzheimer's disease by blocking the activity of SEMA4D.
-
GC69735
Prezalumab
Prezalumab (AMG 557) is a human IgG2 monoclonal antibody that targets ICOSL and BAFF. Prezalumab has been studied for its effects on systemic lupus erythematosus arthritis. Prezalumab can be used in research for skin lupus erythematosus, psoriasis, and systemic lupus erythematosus (SLE).
- GC66381 Relatlimab Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer.
-
GC69826
Rocatinlimab
Rocatinlimab (AMG 451) (KHK4083) is a fully human, non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody against OX40. Rocatinlimab can be used for the study of atopic dermatitis (AD).
-
GC69832
Rosmantuzumab
Rosmantuzumab (OMP-131R10) is a humanized monoclonal antibody that targets R-spondin 3 (RSPO3). It can be used for the study of advanced, recurrent, and refractory solid tumors.
- GC68285 Rosopatamab
- GC64424 Sabatolimab Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses.
- GC65538 Sacituzumab Sacituzumab is a humanized IgG1 monoclonal antibody for anti-trophoblast cell-surface antigen 2 (anti-Trop-2). Sacituzumab has?the?potential?for metastatic triple-negative breast cancer research.
-
GC69855
Samalizumab
Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its connection with the CD200 receptor (CD200R). Samalizumab can be used in research for multiple myeloma and B-cell chronic lymphocytic leukemia.
- GC65512 Selicrelumab Selicrelumab is an agonist CD40 antibody, induces changes in the tumor microenvironment. Selicrelumab can be used for the research of pancreatic cance and neoadjuvant study.
-
GC69887
Sibeprenlimab
Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody. Sibeprenlimab can inhibit APRIL and may be used in the research of IgA nephropathy (IgAN).
-
GC69924
Sofituzumab
Sofituzumab (MMUC 1206A) is a humanized anti-MUC16 recombinant V-kappa antibody.
-
GC69927
Sontuzumab
Sontuzumab (AS1402) is a humanized IgG1κ monoclonal antibody that specifically targets MUC1. Sontuzumab binds to the extracellular peptide sequence PDTR of MUC1 with a Kd of approximately 1 nM. Sontuzumab can be used for research on breast cancer.
- GC68356 Sotigalimab
-
GC69986
Tanezumab
Tanezumab (RN-624) is a humanized monoclonal antibody with high affinity and specificity that can block the binding of NGF to receptors p75 and TrkA in the peripheral nervous system. Tanezumab can be used for acute and chronic pain, such as osteoarthritis, knee joint and neuropathic pain, and postherpetic neuralgia research.
-
GC69996
Tavolixizumab
Tavolixizumab (MEDI 0562; Tavolimab) is a humanized monoclonal antibody against TNFRSF4 (tumor necrosis factor receptor superfamily member 4), which can be used in cancer immunotherapy research.
-
GC70005
Telazorlimab
Telazorlimab (GBR-830) is a humanized monoclonal antibody targeting the OX40 co-stimulatory receptor on activated T cells. Telazorlimab can be used for research in autoimmune diseases.
-
GC70006
Telisotuzumab
Telisotuzumab (ABT-700) is a humanized recombinant bivalent antibody that targets the hepatocyte growth factor receptor (MET) as a therapeutic antibody. It can bind to c-Met with high affinity and inhibit c-Met signaling. Telisotuzumab has anti-tumor activity.
-
GC70008
Telitacicept
Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks the proliferation of B lymphocytes. Telitacicept can be used in research on B cell autoimmune diseases.
-
GC70010
Tenatumomab
Tenatumomab (ST2146) is a mouse-derived monoclonal antibody against tenascin-C, a large extracellular glycoprotein that is overexpressed in cancer. Tenatumomab has been used in pre-targeted radioimmunotherapy studies (PAGRIT), and delivers radioactive isotopes to tumors through PAGRIT and direct 131 iodine labeling methods.
-
GC70018
Tesnatilimab
Tesnatilimab is a humanized IgG4 monoclonal antibody that targets the immune activating receptor NKG2D and has potential immunomodulatory and anti-inflammatory activity. Tesnatilimab can be used in research for inflammatory bowel disease (IBD).
- GC66397 Tinurilimab Tinurilimab (Bay 1834942) is an anti-CEACAM6 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors.
- GC68355 Tiragolumab
-
GC70057
Tregalizumab
Tregalizumab is a humanized monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. It can be used for research on autoimmune diseases (caused by insufficient Treg activity) and allergies.
-
GC70073
TSR-033
TSR-033 is a high-affinity humanized IgG4 antibody targeting LAG-3 (lymphocyte activation gene-3), which enhances T cell function both in vitro and in vivo, as well as PD-1 blocking activity. LAG-3 is a co-inhibitory receptor associated with impaired T cell function and often co-expressed with PD-1. TSR-033 has anti-tumor activity.
- GC68358 Tusamitamab
- GC65501 Urelumab Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab.
-
GC70117
Vibostolimab
Vibostolimab is a monoclonal antibody that targets anti-TIGIT (T cell immunoglobulin and ITIM domain). Vibostolimab has demonstrated anti-tumor activity and can be used in research for non-small cell lung cancer (NSCLC) and melanoma.
-
GC70123
Vonlerolizumab
Vonlerolizumab (MOXR 0916) is a humanized IgG agonistic monoclonal antibody specific for OX40. Vonlerolizumab can be used in cancer research.
-
GC70124
Vopratelimab
Vopratelimab (JTX-2011) is a humanized monoclonal antibody that acts as an agonist of the immune globulin G1-kappa and specifically binds to the inducible T cell co-stimulator (ICOS). Vopratelimab retains cross-species reactivity, with an affinity of 0.93 nM for hICOS, 3.7 nM for rat ICOS, and 0.64 nM for mICOS. Vopratelimab has anti-tumor immune response properties.
-
GC65205
Zolbetuximab
Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors.